FDA. “FDA approves Amjevita, a biosimilar to Humira.”
Kurd, . Journal of the American Academy of Dermatology , April 2008.
Medscape: "FDA OKs Biologic Guselkumab (Tremfya) for Plaque Psoriasis."
Arthritis Foundation: “Latest Treatments for Psoriatic Arthritis.”
National Cancer Institute: "Dictionary of Cancer Terms: Turmeric."
National Psoriasis Foundation: "Complementary approaches: natural elements;" "Over-the-counter (OTC) Topicals;" "Can Diet Heal Psoriasis?" and "Gluten-free Diet."
University of Maryland Medical Center: "Psoriasis -- Treatment."
University of Michigan Health System: "Psoriasis Topic Overview."
University of Maryland Medical Center: "Aloe."
University of Michigan Health System: "Psoriasis."
PUVA is a special treatment using a photosensitizing drug and timed artificial-light exposure composed of wavelengths of ultraviolet light in the UVA spectrum. The photosensitizing drug in PUVA is called psoralen. Both the psoralen and the UVA light must be administered within one hour of each other for a response to occur. These treatments are usually given in a physician's office two to three times per week. Several weeks of PUVA is usually required before seeing significant results. The light exposure time is gradually increased during each subsequent treatment. Psoralens may be given orally as a pill or topically as a bath or lotion. After a short incubation period, the skin is exposed to a special wavelength of ultraviolet light called UVA. Patients using PUVA are generally sun sensitive and must avoid sun exposure for a period of time after PUVA. Common side effects with PUVA include burning, aging of the skin, increased brown spots called lentigines , and an increased risk of skin cancer , including melanoma . The relative increase in skin cancer risk with PUVA treatment is controversial. PUVA treatments need to be closely monitored by a physician and discontinued when a maximum number of treatments have been reached.